Personalized Postoperative Pain Management Following Thoracic Surgery in Adults
The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone, in adults following thoracic surgery. Major inpatient thoracic surg
| Condition(s) | Thoracic Surgery, Pneumonectomy, Lobectomy, Segmentectomy |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone, in adults following thoracic surgery. Major inpatient thoracic surgeries (TS) for lung disease are common and extremely painful surgeries and are associated with sever post-surgical pain, high incidence of chronic post-surgical pain (CPSP), excess opioid use, costly immediate postoperative opioid adverse events (AEs), and long hospital stays. This study is aiming to develop proactive risk prediction algorithms for precision surgical pain relief in adult TS patients through comparison of actual clinical outcomes with standard of care to predi |
| Who can participate | Inclusion Criteria: * \>18 years * American Society of Anesthesiologists (ASA) Physical Status 1, 2, 3 * Undergoing thoracic surgery (TS; pneumonectomy, lobectomy and segmentectomy) Exclusion Criteria: * Children (\<18 years) * Pregnant women * American Society of Anesthesiologists (ASA) Physical Status 4 or above * Non-English speaking * Outpatient surgery * Concomitant additional surgical procedures * Significant liver and kidney dysfunction * Significant cardiorespiratory compromise * Patients with polysubstance use (e.g., cocaine, marijuana, amphetamine, etc.) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Lead sponsor | OpalGenix, Inc |
| Locations | Pittsburgh, Pennsylvania, United States; Pittsburgh, Pennsylvania, United States; Pittsburgh, Pennsylvania, United States; Pittsburgh, Pennsylvania, United States |
| Start date | 2023-11-30 |
| NCT ID | NCT05525923 |
| Official listing | https://clinicaltrials.gov/study/NCT05525923 |